Abstract
Serotonin (5-hydroxytryptamine [5-HT])1 receptor agonists, such as those used for treating migraine, can cause coronary artery contraction, coronary spasm, and even myocardial infarction. Tegaserod maleate is a relatively new 5-HT4 receptor agonist with moderate affinity for the 5-HT1 receptor. Currently, it is approved only for treatment of irritable bowel syndrome in women who have constipation as the primary symptom. However, it is also being administered as a promotility agent in patients with gastroparesis. Since tegaserod has affinity for the 5-HT1 receptor, it is plausible that tegaserod could cause the same types of cardiovascular adverse events seen with agents prescribed for management of migraine. We report the first case of a man who experienced a myocardial infarction after receiving only two 6-mg doses of tegaserod; we also provide a hypothesis regarding this event. When considering prescribing a drug with 5-HT1 receptor agonist activity, clinicians should review the patient's medical history specifically for the presence of underlying cardiovascular risk factors.
Original language | English (US) |
---|---|
Pages (from-to) | 526-531 |
Number of pages | 6 |
Journal | Pharmacotherapy |
Volume | 24 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2004 |
Keywords
- 5-HT receptor agonist
- Cardiovascular adverse events
- Cardiovascular risk factors
- Migraine
- Myocardial infarction
- Tegaserod
- Triptans
ASJC Scopus subject areas
- Pharmacology (medical)